Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly Launches a New Migraine Drug

By Jim Crumly - Updated Feb 3, 2020 at 10:20AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Reyvow is the first drug in an entirely new class of acute migraine treatments.

Eli Lilly (LLY -0.08%) launched its new pill for the acute treatment of migraines Friday after the Drug Enforcement Administration  completed its review of the drug and classified it as having a low potential for abuse or dependence. Reyvow is the first drug of a new class, and treats not only pain, but sensitivity to light, sensitivity to sound, and nausea. It's the first new type of acute migraine drug to come to market in more than two decades.

Reyvow was approved by the Food and Drug Administration in October, but a DEA review was required because it acts on the central nervous system. Now that it has received a favorable decision on the scheduling of the drug, Lilly said it will be available for prescription immediately and will be in pharmacies in the next few days.

Image of a man holding head with sparks coming from brain.

Image source: Getty Images.

The new migraine drug joins Emgality in Lilly's portfolio, the company's relatively new monthly injection for the prevention of migraines. Sales of Emgality have been ramping up quickly -- it  generated $66 million in revenue in the fourth quarter. Lilly thinks it'll be able to leverage the infrastructure and experience from the Emgality launch to strengthen its position with Reyvow.

However, Reyvow has some  will additional competition. Allergan (AGN), which is seeking to merge with AbbVie (ABBV -0.72%), received approval in December for UBRELVY, an oral acute treatment of migraines that's in the same drug class as Emgality, and it is available to patients.

Editor's note: This article has been corrected. UBRELVY is available for prescription. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$322.74 (-0.08%) $0.26
Allergan plc Stock Quote
Allergan plc
AbbVie Inc. Stock Quote
AbbVie Inc.
$153.03 (-0.72%) $-1.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.